Trade Ionis Pharmaceuticals, Inc. - IONS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 40.09 |
| Open | 39.97 |
| 1-Year Change | 13.78% |
| Day's Range | 39.4 - 40.02 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 8, 2024 | 40.09 | -0.15 | -0.37% | 40.24 | 40.76 | 39.96 |
| May 7, 2024 | 40.71 | -0.13 | -0.32% | 40.84 | 41.96 | 40.48 |
| May 6, 2024 | 42.21 | 0.83 | 2.01% | 41.38 | 42.42 | 40.79 |
| May 3, 2024 | 41.86 | -1.27 | -2.94% | 43.13 | 43.47 | 41.76 |
| May 2, 2024 | 43.03 | 0.03 | 0.07% | 43.00 | 43.56 | 42.48 |
| May 1, 2024 | 42.94 | 1.79 | 4.35% | 41.15 | 43.54 | 40.55 |
| Apr 30, 2024 | 41.05 | 0.65 | 1.61% | 40.40 | 42.00 | 40.40 |
| Apr 29, 2024 | 41.91 | 0.62 | 1.50% | 41.29 | 42.25 | 41.29 |
| Apr 26, 2024 | 41.50 | -0.20 | -0.48% | 41.70 | 42.22 | 40.70 |
| Apr 25, 2024 | 41.63 | -0.56 | -1.33% | 42.19 | 42.64 | 41.36 |
| Apr 24, 2024 | 42.38 | 0.87 | 2.10% | 41.51 | 42.60 | 41.51 |
| Apr 23, 2024 | 41.77 | 1.03 | 2.53% | 40.74 | 42.19 | 40.74 |
| Apr 22, 2024 | 41.01 | 0.61 | 1.51% | 40.40 | 41.76 | 40.15 |
| Apr 19, 2024 | 40.58 | 1.57 | 4.02% | 39.01 | 41.07 | 39.01 |
| Apr 18, 2024 | 40.72 | -0.11 | -0.27% | 40.83 | 41.46 | 40.58 |
| Apr 17, 2024 | 40.83 | -0.55 | -1.33% | 41.38 | 41.42 | 40.58 |
| Apr 16, 2024 | 41.34 | 0.02 | 0.05% | 41.32 | 41.92 | 39.83 |
| Apr 15, 2024 | 41.36 | -0.04 | -0.10% | 41.40 | 41.92 | 41.03 |
| Apr 12, 2024 | 41.66 | -0.41 | -0.97% | 42.07 | 42.48 | 41.35 |
| Apr 11, 2024 | 42.44 | -0.43 | -1.00% | 42.87 | 42.87 | 41.88 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ionis Pharmaceuticals Company profile
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; and Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.| Industry: | Biotechnology & Medical Research (NEC) |
2855 Gazelle Court
CARLSBAD
CALIFORNIA 92010
US
News
Bank of England preview: possible rate cut in summer?
The Bank of England (BoE) is widely expected to keep interest rates unchanged when it meets later this week. Data from Reuters shows a 90% chance of no change to the current rate of 5.25%, but the central bank will need to decide whether to change the messaging about rate cuts this year as traders will be paying close attention to any rate-cut clues.
12:39, 8 May 2024
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com